Government-Owned Inventions; Availability for Licensing, 4935 [2015-01610]
Download as PDF
Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices
Dated: January 22, 2015.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2015–01685 Filed 1–28–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
Potential Commercial Applications
• Drug Development
• Toxicity Studies
• Drug Design
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
SUMMARY:
mstockstill on DSK4VPTVN1PROD with NOTICES
Miniature System for Manipulating
Small Animals in High-Throughput
Screening Small Molecules
Description of Technology: The
invention pertains to a miniaturized
plating and feeding system based on a
96-well microplate base and is intended
to reduce manipulation of organisms as
well as amounts of test drug/anesthetic,
thereby mitigating waste. The kit
comprises a feeder plate, transfer
adaptor and receiver plate. The feeder
plate is defined by, for example, a
plastic 96-well plate with rounded
wells. The rounded bottoms can
dispense to or permit access to the test
organism of liquid food or drug through
about 7 holes of approximately 350
microns in diameter. A top portion of
the well provides test organisms (e.g.,
drosophila, daphnia) with sufficient
VerDate Sep<11>2014
18:16 Jan 28, 2015
Jkt 235001
space to enjoy normal life-cycles
without confinement stress. The feeder
plate includes means for interfacing
with complementary components of the
transfer and receiver plates through
receiving holes and complementary
dowels or pins. A transfer adapter
allows the interconnection of the feeder
plate to the receiver plate. The transfer
plate can be configured to be square or
rounded for the transfer of organisms
from the feeder plate to the receiver
plate.
• A LRRK2 inhibitor would be a
unique form of anti-inflammatory
therapy that will complement or
compete with an array of cytokines in
primary treatment for lBD.
• A LRRK2 inhibitor would provide a
much needed alternate mode of therapy.
Small animals
High Throughput
Space efficiency
Resource economy
Development Stage
• Early stage
• Prototype
Inventors: Maria De Los Angeles Jaime
and Brian Oliver (NIDDK).
Intellectual Property: HHS Reference
No. E–034–2015/0—US Provisional
Application No. 62/080,181 filed
November 14, 2015.
Licensing Contact: Michael
Shmilovich, Esq.; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
High-Throughput Small Animal
Manipulation for Drug Design. For
collaboration opportunities, please
contact Marguerite J. Miller at
millermarg@niddk.nih.gov.
LRKK2 Inhibitors: Novel Treatment for
Intestinal Bowel Disorders
Description of Technology: Use of
Leucine Rich Repeat Kinase 2 (LRRK2)
inhibitors for the treatment of Intestinal
Bowel Disorders (IBD) is disclosed. IBD
is a broad term that describes conditions
with chronic or recurring immune
response and inflammation of the
gastrointestinal tract. Crohn’s disease
and ulcerative colitis, two common
forms of idiopathic IBD, are chronic,
relapsing inflammatory disorders of the
gastrointestinal tract.
LRRK2 is a kinase encoded by a gene
that contains a non-coding
polymorphism (SNP). LRRK2 has been
associated with and is a risk factor for
inflammatory bowel disease. NIH
PO 00000
Frm 00083
Fmt 4703
inventors have shown that human cells
expressing this SNP have increased
levels of LRRK2 and, correspondingly,
mice with increased levels of LRRK2
exhibit more severe Dextran Sulfate
colitis. In various studies of the role of
LRRK2 in cell signaling, NIH inventors
have shown that increased levels of
LRRK2 lead to increased proinflammatory cytokine secretion. Also,
an inhibitor of LRRK2 is shown to
abrogate the pro-inflammatory activity
of LRRK2 both in vitro and in vivo.
Potential Commercial Applications:
Treatment for or prevention of Intestinal
Bowel Disorders.
Competitive Advantages
Competitive Advantages
•
•
•
•
4935
Sfmt 4703
Development Stage
• Early-stage
• In vitro data available
• In vivo data available (animal)
Inventors: Warren Strober, Ivan J.
Fuss, Tetsuya Takagawa, Atsushi Kitani
(all of NIAID).
Intellectual Property: HHS Reference
No. E–070–2014/0—US Provisional
Application No. 61/993,637 filed May
15, 2014.
Licensing Contact: Suryanarayana
Vepa, Ph.D., J.D.; 301–435–5020;
vepas@mail.nih.gov.
Dated: January 22, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–01610 Filed 1–28–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\29JAN1.SGM
29JAN1
Agencies
[Federal Register Volume 80, Number 19 (Thursday, January 29, 2015)]
[Notices]
[Page 4935]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01610]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Miniature System for Manipulating Small Animals in High-Throughput
Screening Small Molecules
Description of Technology: The invention pertains to a miniaturized
plating and feeding system based on a 96-well microplate base and is
intended to reduce manipulation of organisms as well as amounts of test
drug/anesthetic, thereby mitigating waste. The kit comprises a feeder
plate, transfer adaptor and receiver plate. The feeder plate is defined
by, for example, a plastic 96-well plate with rounded wells. The
rounded bottoms can dispense to or permit access to the test organism
of liquid food or drug through about 7 holes of approximately 350
microns in diameter. A top portion of the well provides test organisms
(e.g., drosophila, daphnia) with sufficient space to enjoy normal life-
cycles without confinement stress. The feeder plate includes means for
interfacing with complementary components of the transfer and receiver
plates through receiving holes and complementary dowels or pins. A
transfer adapter allows the interconnection of the feeder plate to the
receiver plate. The transfer plate can be configured to be square or
rounded for the transfer of organisms from the feeder plate to the
receiver plate.
Potential Commercial Applications
Drug Development
Toxicity Studies
Drug Design
Competitive Advantages
Small animals
High Throughput
Space efficiency
Resource economy
Development Stage
Early stage
Prototype
Inventors: Maria De Los Angeles Jaime and Brian Oliver (NIDDK).
Intellectual Property: HHS Reference No. E-034-2015/0--US
Provisional Application No. 62/080,181 filed November 14, 2015.
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize High-Throughput
Small Animal Manipulation for Drug Design. For collaboration
opportunities, please contact Marguerite J. Miller at
millermarg@niddk.nih.gov.
LRKK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders
Description of Technology: Use of Leucine Rich Repeat Kinase 2
(LRRK2) inhibitors for the treatment of Intestinal Bowel Disorders
(IBD) is disclosed. IBD is a broad term that describes conditions with
chronic or recurring immune response and inflammation of the
gastrointestinal tract. Crohn's disease and ulcerative colitis, two
common forms of idiopathic IBD, are chronic, relapsing inflammatory
disorders of the gastrointestinal tract.
LRRK2 is a kinase encoded by a gene that contains a non-coding
polymorphism (SNP). LRRK2 has been associated with and is a risk factor
for inflammatory bowel disease. NIH inventors have shown that human
cells expressing this SNP have increased levels of LRRK2 and,
correspondingly, mice with increased levels of LRRK2 exhibit more
severe Dextran Sulfate colitis. In various studies of the role of LRRK2
in cell signaling, NIH inventors have shown that increased levels of
LRRK2 lead to increased pro-inflammatory cytokine secretion. Also, an
inhibitor of LRRK2 is shown to abrogate the pro-inflammatory activity
of LRRK2 both in vitro and in vivo.
Potential Commercial Applications: Treatment for or prevention of
Intestinal Bowel Disorders.
Competitive Advantages
A LRRK2 inhibitor would be a unique form of anti-
inflammatory therapy that will complement or compete with an array of
cytokines in primary treatment for lBD.
A LRRK2 inhibitor would provide a much needed alternate
mode of therapy.
Development Stage
Early-stage
In vitro data available
In vivo data available (animal)
Inventors: Warren Strober, Ivan J. Fuss, Tetsuya Takagawa, Atsushi
Kitani (all of NIAID).
Intellectual Property: HHS Reference No. E-070-2014/0--US
Provisional Application No. 61/993,637 filed May 15, 2014.
Licensing Contact: Suryanarayana Vepa, Ph.D., J.D.; 301-435-5020;
vepas@mail.nih.gov.
Dated: January 22, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-01610 Filed 1-28-15; 8:45 am]
BILLING CODE 4140-01-P